• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人类对HIV-1-Nef的免疫反应。I. 未感染供体的CD45RO-T淋巴细胞中含有高频细胞毒性T淋巴细胞前体。

Human immune response to HIV-1-Nef. I. CD45RO- T lymphocytes of non-infected donors contain cytotoxic T lymphocyte precursors at high frequency.

作者信息

Lucchiari M, Niedermann G, Leipner C, Meyerhans A, Eichmann K, Maier B

机构信息

Max-Planck-Institut für Immunbiologie, Freiburg, Germany.

出版信息

Int Immunol. 1994 Nov;6(11):1739-49. doi: 10.1093/intimm/6.11.1739.

DOI:10.1093/intimm/6.11.1739
PMID:7865467
Abstract

The immune response of peripheral blood lymphocytes (PBL) of non-exposed human individuals to the Nef protein of HIV-1 was studied. Nef is a regulatory protein of HIV which is immediately expressed after infection and which seems to be important in the pathogenicity of HIV. Nef may therefore serve as a potential target for effective immunity against HIV infection. Epstein-Barr (EBV)-transformed lymphoblastoid B cell lines (LCL) were established from four healthy young seronegative adults and transfected with the Nef gene. These cells served as stimulator cells for autologous PBL in vitro and as target cells for CTL. CTL responses were readily generated against Nef-transfected LCL, consisting of Nef-specific and putative EBV-specific CTL. Nef-specific CTL were generated exclusively from CD8+ cells and were MHC class I restricted. Since a vigorous Nef-specific CTL response in non-infected individuals was unexpected, CTL precursor frequencies were determined by limiting dilution analyses in non-fractionated PBL and in PBL separated into the CD45RO- (naive) and CD45RO+ (memory) T cell populations. As expected, the putative EBV-specific CTL precursors were predominantly found in the CD45RO+ subset at frequencies typical for memory T cells. Nef-specific CTL precursors, in contrast, were found predominantly in the CD45RO- population, at even higher frequencies of approximately 1/1000-1/3000. Nef may thus display either an unusually high number of immunogenic peptides or a limited number of peptides presented in a very efficient way, so that many T cells including low affinity cells, would be triggered.

摘要

研究了未接触过HIV的个体外周血淋巴细胞(PBL)对HIV-1 Nef蛋白的免疫反应。Nef是HIV的一种调节蛋白,在感染后立即表达,似乎在HIV的致病性中起重要作用。因此,Nef可能成为有效抵抗HIV感染免疫的潜在靶点。从四名健康的年轻血清阴性成年人中建立了爱泼斯坦-巴尔病毒(EBV)转化的淋巴母细胞样B细胞系(LCL),并用Nef基因进行转染。这些细胞在体外作为自体PBL的刺激细胞以及CTL的靶细胞。针对Nef转染的LCL很容易产生CTL反应,包括Nef特异性和假定的EBV特异性CTL。Nef特异性CTL仅由CD8 +细胞产生,并且受MHC I类限制。由于在未感染个体中出现强烈的Nef特异性CTL反应出乎意料,因此通过有限稀释分析在未分级的PBL以及分离为CD45RO-(幼稚)和CD45RO +(记忆)T细胞群体的PBL中确定CTL前体频率。正如预期的那样,假定的EBV特异性CTL前体主要在CD45RO +亚群中以记忆T细胞典型的频率被发现。相比之下,Nef特异性CTL前体主要在CD45RO-群体中被发现,频率甚至更高,约为1/1000 - 1/3000。因此,Nef可能展示出异常大量的免疫原性肽,或者以非常有效的方式呈现有限数量的肽,从而触发包括低亲和力细胞在内的许多T细胞。

相似文献

1
Human immune response to HIV-1-Nef. I. CD45RO- T lymphocytes of non-infected donors contain cytotoxic T lymphocyte precursors at high frequency.人类对HIV-1-Nef的免疫反应。I. 未感染供体的CD45RO-T淋巴细胞中含有高频细胞毒性T淋巴细胞前体。
Int Immunol. 1994 Nov;6(11):1739-49. doi: 10.1093/intimm/6.11.1739.
2
Human immune response to HIV-1 Nef. II. Induction of HIV-1/HIV-2 Nef cross-reactive cytotoxic T lymphocytes in peripheral blood lymphocytes of non-infected healthy individuals.
Int Immunol. 1996 Apr;8(4):577-84. doi: 10.1093/intimm/8.4.577.
3
Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease.人类免疫缺陷病毒1型(HIV-1)感染不同阶段HIV-1特异性细胞毒性T淋巴细胞(CTL)反应的定量分析:疾病晚期对HIV-1和爱泼斯坦-巴尔病毒的不同CTL反应
J Exp Med. 1993 Feb 1;177(2):249-56. doi: 10.1084/jem.177.2.249.
4
A novel method for detection and ex vivo expansion of HIV type 1-specific cytolytic T lymphocytes.一种用于检测和体外扩增1型人类免疫缺陷病毒特异性细胞毒性T淋巴细胞的新方法。
AIDS Res Hum Retroviruses. 1994 Nov;10(11):1427-31. doi: 10.1089/aid.1994.10.1427.
5
Efficient antigen presentation to cytotoxic T lymphocytes by cells transduced with a retroviral vector expressing the HIV-1 Nef protein.通过用表达HIV-1 Nef蛋白的逆转录病毒载体转导的细胞向细胞毒性T淋巴细胞有效呈递抗原。
AIDS Res Hum Retroviruses. 1993 Dec;9(12):1217-23. doi: 10.1089/aid.1993.9.1217.
6
CD8(+)-Cell antiviral factor activity is not restricted to human immunodeficiency virus (HIV)-specific T cells and can block HIV replication after initiation of reverse transcription.CD8(+)细胞抗病毒因子的活性并不局限于人类免疫缺陷病毒(HIV)特异性T细胞,并且在逆转录开始后能够阻断HIV复制。
J Virol. 2000 May;74(10):4456-64. doi: 10.1128/jvi.74.10.4456-4464.2000.
7
HIV-1-specific CTL responses primed in vitro by blood-derived dendritic cells and Th1-biasing cytokines.由血液来源的树突状细胞和Th1偏向性细胞因子在体外引发的HIV-1特异性CTL反应。
J Immunol. 1999 Mar 1;162(5):3070-8.
8
Human cytotoxic T lymphocytes. III. Large numbers of peripheral blood T cells clonally develop into allorestricted anti-viral cytotoxic T cell populations in vitro.人细胞毒性T淋巴细胞。III. 大量外周血T细胞在体外克隆性发育成同种异体限制性抗病毒细胞毒性T细胞群体。
J Mol Cell Immunol. 1987;3(1):49-60.
9
Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.针对 Epstein-Barr 病毒(EBV)转化的 B 淋巴母细胞系产生的、受 I 类主要组织相容性复合体限制的细胞毒性 T 淋巴细胞。 这些细胞毒性 T 淋巴细胞对它们所针对的 EBV 转化的 B 淋巴母细胞系具有特异性。
J Exp Med. 1995 Jun 1;181(6):2221-8. doi: 10.1084/jem.181.6.2221.
10
Carboxyl-terminal and central regions of human immunodeficiency virus-1 NEF recognized by cytotoxic T lymphocytes from lymphoid organs. An in vitro limiting dilution analysis.来自淋巴器官的细胞毒性T淋巴细胞所识别的人类免疫缺陷病毒1型NEF的羧基末端和中央区域。一项体外有限稀释分析。
J Clin Invest. 1992 Jan;89(1):53-60. doi: 10.1172/JCI115585.

引用本文的文献

1
Trafficking through the Rev/RRE pathway is essential for efficient inhibition of human immunodeficiency virus type 1 by an antisense RNA derived from the envelope gene.通过Rev/RRE途径的转运对于源自包膜基因的反义RNA有效抑制1型人类免疫缺陷病毒至关重要。
J Virol. 2009 Jan;83(2):940-52. doi: 10.1128/JVI.01520-08. Epub 2008 Oct 29.
2
Human immunodeficiency virus type 1 Nef associates with lipid rafts to downmodulate cell surface CD4 and class I major histocompatibility complex expression and to increase viral infectivity.1型人类免疫缺陷病毒Nef与脂筏结合,以下调细胞表面CD4和I类主要组织相容性复合体的表达,并增加病毒感染性。
J Virol. 2004 Feb;78(4):1685-96. doi: 10.1128/jvi.78.4.1685-1696.2004.
3
Design and use of an inducibly activated human immunodeficiency virus type 1 Nef to study immune modulation.
用于研究免疫调节的可诱导激活的1型人类免疫缺陷病毒Nef的设计与应用。
J Virol. 2001 Jan;75(2):834-43. doi: 10.1128/JVI.75.2.834-843.2001.
4
Cytotoxic T lymphocyte epitopes of HIV-1 Nef: Generation of multiple definitive major histocompatibility complex class I ligands by proteasomes.HIV-1 Nef的细胞毒性T淋巴细胞表位:蛋白酶体产生多种明确的主要组织相容性复合体I类配体
J Exp Med. 2000 Jan 17;191(2):239-52. doi: 10.1084/jem.191.2.239.
5
An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions.转移性黑色素瘤患者中针对细胞毒性T淋巴细胞(CTL)定义的黑色素细胞特异性抗原的外周T细胞群体扩增,会影响肽特异性CTL的产生,但无法克服转移病灶中肿瘤对免疫监视的逃逸。
J Exp Med. 1999 Sep 6;190(5):651-67. doi: 10.1084/jem.190.5.651.
6
HIV-specific T cell cytotoxicity mediated by RANTES via the chemokine receptor CCR3.由趋化因子RANTES通过趋化因子受体CCR3介导的HIV特异性T细胞细胞毒性。
J Exp Med. 1998 Aug 3;188(3):609-14. doi: 10.1084/jem.188.3.609.
7
Herpesvirus saimiri-transformed human CD4+ T-cell lines: an efficient target cell system for the analysis of human immunodeficiency virus-specific cytotoxic CD8+ T-lymphocyte activity.猴疱疹病毒转化的人CD4 + T细胞系:用于分析人免疫缺陷病毒特异性细胞毒性CD8 + T淋巴细胞活性的高效靶细胞系统。
J Virol. 1998 Feb;72(2):1627-31. doi: 10.1128/JVI.72.2.1627-1631.1998.
8
Genetic drift can dominate short-term human immunodeficiency virus type 1 nef quasispecies evolution in vivo.基因漂变可主导体内1型人类免疫缺陷病毒辅助蛋白nef准种的短期进化。
J Virol. 1997 Jun;71(6):4233-40. doi: 10.1128/JVI.71.6.4233-4240.1997.